Mersana raises $35m, names former Millennium president CEO
This article was originally published in Scrip
Executive Summary
Seventeen-year Millennium Pharmaceuticals veteran Anna Protopapas began her first day as president and CEO of Mersana Therapeutics on 2 March with an announcement that the antibody-drug conjugate (ADC) specialist closed a $35m Series B venture capital round.
You may also be interested in...
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.